Insights on the Metabolic Disorders Drugs Global Market to 2030

Bozz District

DUBLIN, May 18, 2021 /PRNewswire/ — The “Metabolic Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to ResearchAndMarkets.com’s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs market as […]

DUBLIN, May 18, 2021 /PRNewswire/ — The “Metabolic Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to ResearchAndMarkets.com’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs market as it emerges from the COVID-19 shut down.

The global metabolic disorders drugs market is expected to grow from $143.16 billion in 2020 to $146.25 billion in 2021 at a compound annual growth rate (CAGR) of 2.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $198.07 billion in 2025 at a CAGR of 8%.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Where is the largest and fastest growing market for the metabolic disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Metabolic Disorders Drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider metabolic disorders drugs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The metabolic disorders drugs market section of the report gives context. It compares the metabolic disorders drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, metabolic disorders drugs indicators comparison.

Major companies in the metabolic disorders drugs market include Sanofi S.A; Novo Nordisk A/S; AstraZeneca Plc; Johnson & Johnson and Merck & Co.

The metabolic disorders drugs market consists of sales of metabolic disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce metabolic disorders drugs to treat metabolic diseases. This industry includes establishments that produce drugs such as insulin, pramlintide and other drugs to treat diabetes, anti-thyroid drugs to treat hyperthyroidism, and other drugs to treat pituitary gland, adrenal gland and parathyroid gland disorders. The metabolic disorders drugs market is segmented into anti diabetic drugs; anti-thyroid drugs; and others (hyperparathyroidism, hypopituitarism, hypoadrenalism).

North America was the largest region in the global metabolic disorders drugs market, accounting for 54% of the market in 2020. Asia Pacific was the second largest region accounting for 24% of the global metabolic disorders drugs market. Africa was the smallest region in the global metabolic disorders drugs market.

Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information. This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases.

Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the metabolic disorders drugs industry in the historic period.

The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. These factors are expected to increase the patient pool globally, thereby driving the metabolic disorders drugs market during the forecast period.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Metabolic Disorders Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations

4. Metabolic Disorders Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products

5. Metabolic Disorders Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers

6. Metabolic Disorders Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth

7. Metabolic Disorders Drugs Market Trends and Strategies

8. Impact of COVID-19 on Metabolic Disorders Drugs

9. Metabolic Disorders Drugs Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market

10. Metabolic Disorders Drugs Market Regional Analysis
10.1. Global Metabolic Disorders Drugs Market, 2020, by Region, Value ($ Billion)
10.2. Global Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Metabolic Disorders Drugs Market, Growth and Market Share Comparison, by Region

11. Metabolic Disorders Drugs Market Segmentation
11.1. Global Metabolic Disorders Drugs Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Global Metabolic Disorders Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.3. Global Metabolic Disorders Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.4. Global Metabolic Disorders Drugs Market, Segmentation by Drug Classification, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.5. Global Metabolic Disorders Drugs Market, Segmentation by Mode of Purchase, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Metabolic Disorders Drugs Market Metrics
12.1. Metabolic Disorders Drugs Market Size, Percentage of GDP, 2015-2025, Global
12.2. Per Capita Average Metabolic Disorders Drugs Market Expenditure, 2015-2025, Global

13. Asia-Pacific Metabolic Disorders Drugs Market

14. Western Europe Metabolic Disorders Drugs Market

15. Eastern Europe Metabolic Disorders Drugs Market

16. North America Metabolic Disorders Drugs Market

17. South America Metabolic Disorders Drugs Market

18. Middle East Metabolic Disorders Drugs Market

19. Africa Metabolic Disorders Drugs Market

20. Metabolic Disorders Drugs Market Competitive Landscape
20.1. Competitive Market Overview
20.2. Market Shares
20.3. Company Profiles
20.3.1. Sanofi S.A
20.3.1.1. Company Overview
20.3.1.2. Products and Services
20.3.1.3. Strategy
20.3.1.4. Financial Performance
20.3.2. Novo Nordisk A/S
20.3.2.1. Company Overview
20.3.2.2. Products and Services
20.3.2.3. Strategy
20.3.2.4. Financial Performance
20.3.3. AstraZeneca Plc
20.3.3.1. Company Overview
20.3.3.2. Products and Services
20.3.3.3. Strategy
20.3.3.4. Financial Performance
20.3.4. Johnson & Johnson
20.3.4.1. Company Overview
20.3.4.2. Products and Services
20.3.4.3. Strategy
20.3.4.4. Financial Performance
20.3.5. Merck & Co
20.3.5.1. Company Overview
20.3.5.2. Products and Services
20.3.5.3. Strategy
20.3.5.4. Financial Performance

21. Key Mergers and Acquisitions in the Metabolic Disorders Drugs Market

22. Market Background: Pharmaceutical Drugs Market
22.1. Pharmaceutical Drugs Market Characteristics
22.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
22.3. Global Pharmaceutical Drugs Market, 2020, by Region, Value ($ Billion)
22.4. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
22.5. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)

23. Recommendations
23.1. Global Metabolic Disorders Drugs Market in 2025 – Growth Countries
23.2. Global Metabolic Disorders Drugs Market in 2025 – Growth Segments
23.3. Global Metabolic Disorders Drugs Market in 2025 – Growth Strategies

24. Appendix

25. Copyright and Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/7wa26w

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Next Post

A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection

INTRODUCTION As of January 2021, the recently emerged severe-acute respiratory syndrome coronavirus 2 has led to over 2 million deaths and over 100 million infections globally (1). SARS-CoV-2 is a member of the Coronaviridae family of viruses. Respiratory infections with SARS-CoV-2 can result in asymptomatic, mild or severe forms of […]